LONDON, Nov. 6, 2023 -- The life sciences profession is in the midst of a profound transformation, guided by the revolutionary force of artificial intelligence (AI), and especially predictive and generative AI models. These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.
The second annual Bio-IT World Conference & Expo Europe in London, coming up 29-30 November, is designed as an innovation hub to help break even more boundaries. Leading experts from academia, government, biopharma, and industry will discuss the exciting work that's already in progress, share data and case studies, and network with others who can help advance their goals.
Among organizations presenting on topics of artificial intelligence, machine learning, and generative AI are ACD/Labs, AstraZeneca, BioAI Health, Clarivate, Expert Systems, GEDiCube, Janssen R&D - Global Development, NIHR Barts Biomedical Research Centre/Queen Mary University of London, Owkin, Poznan Supercomputing and Networking Center, Roche Information Solutions, and Zealand Pharma A/S.
Predictive AI, fueled by vast data reserves, identifies promising drug candidates, predicts their efficacy, and forecasts potential side effects, streamlining the early research stages. In parallel, generative AI refines molecular design with exquisite precision, drastically curtailing the time and resources necessary for drug development.
"The bio-IT community has always been at the forefront of leveraging AI with the important goal of increasing therapeutic efficacy," said Cindy Crowninshield, RDN, LDN, Executive Event Director. "As general interest in AI explodes, our distinguished speakers have valuable information to share about its evolving role in precision medicine."
Among presentation topics in the AI track—one of five tracks into which 60+ sessions will be organized, are:
· Unlocking the Potential of AI in Precision Health: Overcoming Data Challenges for Personalized
Care and Early Disease Detection
· Building AI/ML Models for Data Insights to Facilitate Drug Discovery Pipelines
· Augmenting Drug Discovery with Cloud-Based Predictive Insights at AstraZeneca?
· Predictive and Generative AI in Peptide Drug Discovery?
AI and data-enabled innovations will also be themes of Plenary Keynote Addresses on MOSAIC: A Global Initiative to Deploy Spatial Omics and AI against Cancer; East London: A Global Hub for Digital Precision Medicine; and Data Citizenship and Changing Data Culture.